Manufacturer of Controlled Substances Notice of Application

---
identifier: "/us/fr/03-1914"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Manufacturer of Controlled Substances Notice of Application"
title_number: 0
title_name: "Federal Register"
section_number: "03-1914"
section_name: "Manufacturer of Controlled Substances Notice of Application"
positive_law: false
currency: "2003-01-28"
last_updated: "2003-01-28"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Justice Department"
document_number: "03-1914"
document_type: "notice"
publication_date: "2003-01-28"
agencies:
  - "Justice Department"
  - "Drug Enforcement Administration"
fr_citation: "68 FR 4233"
fr_volume: 68
---


#  Manufacturer of Controlled Substances Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 21, 2002, Bristol-Myers Squibb Pharma Company, 1000 Stewart Avenue, Garden City, New York 11530, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

| Drug | Schedule |
| --- | --- |
| Oxycodone (9143) | II |
| Hydrocodone (9193) | II |
| Oxymorphone (9652) | II |

The firm plans to manufacture the listed controlled substances to make finished products.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representatives (CCR), and must be filed no later than (60 days from publication).

Dated: January 6, 2003.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.